当前位置: 首页 >> 检索结果
401. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
作者: Arun J Sanyal.;Pierre Bedossa.;Mandy Fraessdorf.;Guy W Neff.;Eric Lawitz.;Elisabetta Bugianesi.;Quentin M Anstee.;Samina Ajaz Hussain.;Philip N Newsome.;Vlad Ratziu.;Azadeh Hosseini-Tabatabaei.;Jörn M Schattenberg.;Mazen Noureddin.;Naim Alkhouri.;Ramy Younes.; .
来源: N Engl J Med. 2024年391卷4期311-319页
Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and GLP-1 receptor) in persons with MASH and liver fibrosis are unclear.
402. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D.
作者: Tarik Asselah.;Vladimir Chulanov.;Pietro Lampertico.;Heiner Wedemeyer.;Adrian Streinu-Cercel.;Victor Pântea.;Stefan Lazar.;Gheorghe Placinta.;George S Gherlan.;Pavel Bogomolov.;Tatyana Stepanova.;Viacheslav Morozov.;Vladimir Syutkin.;Olga Sagalova.;Dmitry Manuilov.;Renee-Claude Mercier.;Lei Ye.;Ben L Da.;Grace Chee.;Audrey H Lau.;Anu Osinusi.;Marc Bourliere.;Vlad Ratziu.;Stanislas Pol.;Marie-Noëlle Hilleret.;Fabien Zoulim.
来源: N Engl J Med. 2024年391卷2期133-143页
In a phase 3 trial, bulevirtide monotherapy led to a virologic response in patients with chronic hepatitis D. Pegylated interferon (peginterferon) alfa-2a is recommended by guidelines as an off-label treatment for this disease. The role of combination therapy with bulevirtide and peginterferon alfa-2a, particularly with regard to finite treatment, is unclear.
403. Genome Sequencing for Diagnosing Rare Diseases.
作者: Monica H Wojcik.;Gabrielle Lemire.;Eva Berger.;Maha S Zaki.;Mariel Wissmann.;Wathone Win.;Susan M White.;Ben Weisburd.;Dagmar Wieczorek.;Leigh B Waddell.;Jeffrey M Verboon.;Grace E VanNoy.;Ana Töpf.;Tiong Yang Tan.;Steffen Syrbe.;Vincent Strehlow.;Volker Straub.;Sarah L Stenton.;Hana Snow.;Moriel Singer-Berk.;Josh Silver.;Shirlee Shril.;Eleanor G Seaby.;Ronen Schneider.;Vijay G Sankaran.;Alba Sanchis-Juan.;Kathryn A Russell.;Karit Reinson.;Gianina Ravenscroft.;Maximilian Radtke.;Denny Popp.;Tilman Polster.;Konrad Platzer.;Eric A Pierce.;Emily M Place.;Sander Pajusalu.;Lynn Pais.;Katrin Õunap.;Ikeoluwa Osei-Owusu.;Henry Opperman.;Volkan Okur.;Kaisa Teele Oja.;Melanie O'Leary.;Emily O'Heir.;Chantal F Morel.;Andreas Merkenschlager.;Rhett G Marchant.;Brian E Mangilog.;Jill A Madden.;Daniel MacArthur.;Alysia Lovgren.;Jordan P Lerner-Ellis.;Jasmine Lin.;Nigel Laing.;Friedhelm Hildebrandt.;Julia Hentschel.;Emily Groopman.;Julia Goodrich.;Joseph G Gleeson.;Roula Ghaoui.;Casie A Genetti.;Janina Gburek-Augustat.;Hanna T Gazda.;Vijay S Ganesh.;Mythily Ganapathi.;Lyndon Gallacher.;Jack M Fu.;Emily Evangelista.;Eleina England.;Sandra Donkervoort.;Stephanie DiTroia.;Sandra T Cooper.;Wendy K Chung.;John Christodoulou.;Katherine R Chao.;Liam D Cato.;Kinga M Bujakowska.;Samantha J Bryen.;Harrison Brand.;Carsten G Bönnemann.;Alan H Beggs.;Samantha M Baxter.;Tobias Bartolomaeus.;Pankaj B Agrawal.;Michael Talkowski.;Christina Austin-Tse.;Rami Abou Jamra.;Heidi L Rehm.;Anne O'Donnell-Luria.
来源: N Engl J Med. 2024年390卷21期1985-1997页
Genetic variants that cause rare disorders may remain elusive even after expansive testing, such as exome sequencing. The diagnostic yield of genome sequencing, particularly after a negative evaluation, remains poorly defined.
404. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.
作者: Myriam Chalabi.;Yara L Verschoor.;Pedro Batista Tan.;Sara Balduzzi.;Anja U Van Lent.;Cecile Grootscholten.;Simone Dokter.;Nikè V Büller.;Brechtje A Grotenhuis.;Koert Kuhlmann.;Jacobus W Burger.;Inge L Huibregtse.;Tjeerd S Aukema.;Eduard R Hendriks.;Steven J Oosterling.;Petur Snaebjornsson.;Emile E Voest.;Lodewyk F Wessels.;Regina G Beets-Tan.;Monique E Van Leerdam.;Ton N Schumacher.;José G van den Berg.;Geerard L Beets.;John B Haanen.
来源: N Engl J Med. 2024年390卷21期1949-1958页
Mismatch repair-deficient (dMMR) tumors can be found in 10 to 15% of patients with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited. The use of neoadjuvant immunotherapy has shown promising results, but data from studies of this approach are limited.
405. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
作者: Thierry Facon.;Meletios-Athanasios Dimopoulos.;Xavier P Leleu.;Meral Beksac.;Ludek Pour.;Roman Hájek.;Zhuogang Liu.;Jiri Minarik.;Philippe Moreau.;Joanna Romejko-Jarosinska.;Ivan Spicka.;Vladimir I Vorobyev.;Britta Besemer.;Tadao Ishida.;Wojciech Janowski.;Sevgi Kalayoglu-Besisik.;Gurdeep Parmar.;Pawel Robak.;Elena Zamagni.;Hartmut Goldschmidt.;Thomas G Martin.;Salomon Manier.;Mohamad Mohty.;Corina Oprea.;Marie-France Brégeault.;Sandrine Macé.;Christelle Berthou.;David Bregman.;Zandra Klippel.;Robert Z Orlowski.; .
来源: N Engl J Med. 2024年391卷17期1597-1609页
Bortezomib, lenalidomide, and dexamethasone (VRd) is a preferred first-line treatment option for patients with newly diagnosed multiple myeloma. Whether the addition of the anti-CD38 monoclonal antibody isatuximab to the VRd regimen would reduce the risk of disease progression or death among patients ineligible to undergo transplantation is unclear.
406. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.
作者: Christian U Blank.;Minke W Lucas.;Richard A Scolyer.;Bart A van de Wiel.;Alexander M Menzies.;Marta Lopez-Yurda.;Lotte L Hoeijmakers.;Robyn P M Saw.;Judith M Lijnsvelt.;Nigel G Maher.;Saskia M Pulleman.;Maria Gonzalez.;Alejandro Torres Acosta.;Winan J van Houdt.;Serigne N Lo.;Anke M J Kuijpers.;Andrew Spillane.;W Martin C Klop.;Thomas E Pennington.;Charlotte L Zuur.;Kerwin F Shannon.;Beatrijs A Seinstra.;Robert V Rawson.;John B A G Haanen.;Sydney Ch'ng.;Kishan A T Naipal.;Jonathan Stretch.;Johannes V van Thienen.;Michael A Rtshiladze.;Sofie Wilgenhof.;Rony Kapoor.;Aafke Meerveld-Eggink.;Lindsay G Grijpink-Ongering.;Alexander C J van Akkooi.;Irene L M Reijers.;David E Gyorki.;Dirk J Grünhagen.;Frank M Speetjens.;Sonja B Vliek.;Joanna Placzke.;Lavinia Spain.;Robert C Stassen.;Mona Amini-Adle.;Céleste Lebbé.;Mark B Faries.;Caroline Robert.;Paolo A Ascierto.;Rozemarijn van Rijn.;Franchette W P J van den Berkmortel.;Djura Piersma.;Andre van der Westhuizen.;Gerard Vreugdenhil.;Maureen J B Aarts.;Marion A M Stevense-den Boer.;Victoria Atkinson.;Muhammad Khattak.;Miles C Andrews.;Alfons J M van den Eertwegh.;Marye J Boers-Sonderen.;Geke A P Hospers.;Matteo S Carlino.;Jan-Willem B de Groot.;Ellen Kapiteijn.;Karijn P M Suijkerbuijk.;Piotr Rutkowski.;Shahneen Sandhu.;Astrid A M van der Veldt.;Georgina V Long.
来源: N Engl J Med. 2024年391卷18期1696-1708页
In phase 1-2 trials in patients with resectable, macroscopic stage III melanoma, neoadjuvant immunotherapy was more efficacious than adjuvant immunotherapy.
407. Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
作者: Richard J Auchus.;Oksana Hamidi.;Rosario Pivonello.;Irina Bancos.;Gianni Russo.;Selma F Witchel.;Andrea M Isidori.;Patrice Rodien.;Umasuthan Srirangalingam.;Florian W Kiefer.;Henrik Falhammar.;Deborah P Merke.;Nicole Reisch.;Kyriakie Sarafoglou.;Gordon B Cutler.;Julia Sturgeon.;Eiry Roberts.;Vivian H Lin.;Jean L Chan.;Robert H Farber.; .
来源: N Engl J Med. 2024年391卷6期504-514页
Adrenal insufficiency in patients with classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH) is treated with glucocorticoid replacement therapy. Control of adrenal-derived androgen excess usually requires supraphysiologic glucocorticoid dosing, which predisposes patients to glucocorticoid-related complications. Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels in phase 2 trials involving patients with CAH.
408. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
作者: Meletios Athanasios Dimopoulos.;Meral Beksac.;Ludek Pour.;Sosana Delimpasi.;Vladimir Vorobyev.;Hang Quach.;Ivan Spicka.;Jakub Radocha.;Pawel Robak.;Kihyun Kim.;Michele Cavo.;Kazuhito Suzuki.;Kristin Morris.;Farrah Pompilus.;Amy Phillips-Jones.;Xiaoou L Zhou.;Giulia Fulci.;Neal Sule.;Brandon E Kremer.;Joanna Opalinska.;María-Victoria Mateos.;Suzanne Trudel.; .
来源: N Engl J Med. 2024年391卷5期408-421页
Triplet or quadruplet therapies incorporating proteasome inhibitors, immunomodulators, and anti-CD38 antibodies have led to prolonged survival among patients with newly diagnosed multiple myeloma; however, most patients have a relapse. Frontline lenalidomide therapy has increased the number of patients with lenalidomide-refractory disease at the time of the first relapse.
409. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
作者: Shun Lu.;Terufumi Kato.;Xiaorong Dong.;Myung-Ju Ahn.;Le-Van Quang.;Nopadol Soparattanapaisarn.;Takako Inoue.;Chih-Liang Wang.;Meijuan Huang.;James Chih-Hsin Yang.;Manuel Cobo.;Mustafa Özgüroğlu.;Ignacio Casarini.;Dang-Van Khiem.;Virote Sriuranpong.;Eduardo Cronemberger.;Toshiaki Takahashi.;Yotsawaj Runglodvatana.;Ming Chen.;Xiangning Huang.;Ellie Grainger.;Dana Ghiorghiu.;Toon van der Gronde.;Suresh S Ramalingam.; .
来源: N Engl J Med. 2024年391卷7期585-597页
Osimertinib is a recommended treatment for advanced non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) mutation and as adjuvant treatment for resected EGFR-mutated NSCLC. EGFR tyrosine kinase inhibitors have shown preliminary efficacy in unresectable stage III EGFR-mutated NSCLC.
410. Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.
作者: Kyriakie Sarafoglou.;Mimi S Kim.;Maya Lodish.;Eric I Felner.;Laetitia Martinerie.;Natalie J Nokoff.;María Clemente.;Patricia Y Fechner.;Maria G Vogiatzi.;Phyllis W Speiser.;Richard J Auchus.;Gelliza B G Rosales.;Eiry Roberts.;George S Jeha.;Robert H Farber.;Jean L Chan.; .
来源: N Engl J Med. 2024年391卷6期493-503页
Children with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency require treatment with glucocorticoids, usually at supraphysiologic doses, to address cortisol insufficiency and reduce excess adrenal androgens. However, such treatment confers a predisposition to glucocorticoid-related complications. In 2-week phase 2 trials, patients with CAH who received crinecerfont, a new oral corticotropin-releasing factor type 1 receptor antagonist, had decreases in androstenedione levels.
411. Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.
作者: Vania Hungria.;Pawel Robak.;Marek Hus.;Vera Zherebtsova.;Christopher Ward.;P Joy Ho.;Ana Carolina Ribas de Almeida.;Roman Hajek.;Kihyun Kim.;Sebastian Grosicki.;Hanlon Sia.;Adam Bryant.;Marcelo Pitombeira de Lacerda.;Gracia Aparecida Martinez.;Anna Maria Sureda Balarí.;Irwindeep Sandhu.;Claudio Cerchione.;Peter Ganly.;Meletios Dimopoulos.;Chengcheng Fu.;Mamta Garg.;Al-Ola Abdallah.;Albert Oriol.;Moshe E Gatt.;Michele Cavo.;Robert Rifkin.;Tomoaki Fujisaki.;Michał Mielnik.;Nick Pirooz.;Astrid McKeown.;Simon McNamara.;Xiangdong Zhou.;Maureen Nichols.;Eric Lewis.;Rachel Rogers.;Hena Baig.;Lydia Eccersley.;Sumita Roy-Ghanta.;Joanna Opalinska.;María-Victoria Mateos.; .
来源: N Engl J Med. 2024年391卷5期393-407页
Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies.
412. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
作者: Andreas Hochhaus.;Jianxiang Wang.;Dong-Wook Kim.;Dennis Dong Hwan Kim.;Jiri Mayer.;Yeow-Tee Goh.;Philipp le Coutre.;Naoto Takahashi.;Inho Kim.;Gabriel Etienne.;David Andorsky.;Ghayas C Issa.;Richard A Larson.;Felice Bombaci.;Shruti Kapoor.;Tracey McCulloch.;Kamel Malek.;Lillian Yau.;Sophie Ifrah.;Matthias Hoch.;Jorge E Cortes.;Timothy P Hughes.; .
来源: N Engl J Med. 2024年391卷10期885-898页
Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term therapy with high efficacy and safety. Asciminib, a BCR::ABL1 inhibitor specifically targeting the ABL myristoyl pocket, may offer better efficacy and safety and fewer side effects than currently available frontline ATP-competitive tyrosine kinase inhibitors (TKIs).
413. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks.
作者: Marc A Riedl.;Henriette Farkas.;Emel Aygören-Pürsün.;Fotis Psarros.;Daniel F Soteres.;Maria Staevska.;Mauro Cancian.;David Hagin.;Daisuke Honda.;Isaac Melamed.;Sinisa Savic.;Marcin Stobiecki.;Paula J Busse.;Eunice Dias de Castro.;Nancy Agmon-Levin.;Richard Gower.;Aharon Kessel.;Marcin Kurowski.;Ramon Lleonart.;Vesna Grivcheva Panovska.;H James Wedner.;Paul K Audhya.;James Hao.;Matthew Iverson.;Michael D Smith.;Christopher M Yea.;William R Lumry.;Andrea Zanichelli.;Jonathan A Bernstein.;Marcus Maurer.;Danny M Cohn.; .
来源: N Engl J Med. 2024年391卷1期32-43页
Approved on-demand treatments for hereditary angioedema attacks need to be administered parenterally, a route of administration that is associated with delays in treatment or withholding of therapy.
414. Efficacy and Safety of Donidalorsen for Hereditary Angioedema.
作者: Marc A Riedl.;Raffi Tachdjian.;William R Lumry.;Timothy Craig.;Gül Karakaya.;Asli Gelincik.;Marcin Stobiecki.;Joshua S Jacobs.;Nihal M Gokmen.;Avner Reshef.;Mark M Gompels.;Michael E Manning.;Laura Bordone.;Kenneth B Newman.;Sabrina Treadwell.;Sophie Wang.;Aaron Yarlas.;Danny M Cohn.; .
来源: N Engl J Med. 2024年391卷1期21-31页
Hereditary angioedema is a rare disorder characterized by episodic, potentially life-threatening swelling caused by kallikrein-kinin dysregulation. Long-term prophylaxis can stabilize this system. Donidalorsen, an antisense oligonucleotide, specifically reduces prekallikrein expression.
415. The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1.
作者: Vasileios Oikonomou.;Grace Smith.;Gregory M Constantine.;Monica M Schmitt.;Elise M N Ferré.;Julie C Alejo.;Deanna Riley.;Dhaneshwar Kumar.;Lucas Dos Santos Dias.;Joseph Pechacek.;Yannis Hadjiyannis.;Taura Webb.;Bryce A Seifert.;Rajarshi Ghosh.;Magdalena Walkiewicz.;Daniel Martin.;Marine Besnard.;Brendan D Snarr.;Shiva Deljookorani.;Chyi-Chia R Lee.;Tom DiMaggio.;Princess Barber.;Lindsey B Rosen.;Aristine Cheng.;Andre Rastegar.;Adriana A de Jesus.;Jennifer Stoddard.;Hye Sun Kuehn.;Timothy J Break.;Heidi H Kong.;Leslie Castelo-Soccio.;Ben Colton.;Blake M Warner.;David E Kleiner.;Martha M Quezado.;Jeremy L Davis.;Kevin P Fennelly.;Kenneth N Olivier.;Sergio D Rosenzweig.;Anthony F Suffredini.;Mark S Anderson.;Marc Swidergall.;Carole Guillonneau.;Luigi D Notarangelo.;Raphaela Goldbach-Mansky.;Olaf Neth.;Maria Teresa Monserrat-Garcia.;Justo Valverde-Fernandez.;Jose Manuel Lucena.;Ana Lucia Gomez-Gila.;Angela Garcia Rojas.;Mikko R J Seppänen.;Jouko Lohi.;Matti Hero.;Saila Laakso.;Paula Klemetti.;Vanja Lundberg.;Olov Ekwall.;Peter Olbrich.;Karen K Winer.;Behdad Afzali.;Niki M Moutsopoulos.;Steven M Holland.;Theo Heller.;Stefania Pittaluga.;Michail S Lionakis.
来源: N Engl J Med. 2024年390卷20期1873-1884页
Autoimmune polyendocrine syndrome type 1 (APS-1) is a life-threatening, autosomal recessive syndrome caused by autoimmune regulator (AIRE) deficiency. In APS-1, self-reactive T cells escape thymic negative selection, infiltrate organs, and drive autoimmune injury. The effector mechanisms governing T-cell-mediated damage in APS-1 remain poorly understood.
416. Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia.
作者: Robert S Rosenson.;Daniel Gaudet.;Robert A Hegele.;Christie M Ballantyne.;Stephen J Nicholls.;Kathryn J Lucas.;Javier San Martin.;Rong Zhou.;Ma'an Muhsin.;Ting Chang.;Jennifer Hellawell.;Gerald F Watts.; .
来源: N Engl J Med. 2024年391卷10期913-925页
Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases and hepatic uptake of triglyceride-rich lipoprotein remnants. ANGPTL3 loss-of-function carriers have lower levels of triglycerides, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and non-HDL cholesterol and a lower risk of atherosclerotic cardiovascular disease than noncarriers. Zodasiran is an RNA interference (RNAi) therapy targeting expression of ANGPTL3 in the liver.
417. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia.
作者: Christie M Ballantyne.;Szilard Vasas.;Masoud Azizad.;Peter Clifton.;Robert S Rosenson.;Ting Chang.;Stacey Melquist.;Rong Zhou.;Ma'an Mushin.;Nicholas J Leeper.;Jennifer Hellawell.;Daniel Gaudet.
来源: N Engl J Med. 2024年391卷10期899-912页
Persons with mixed hyperlipidemia are at risk for atherosclerotic cardiovascular disease due to an elevated non-high-density lipoprotein (HDL) cholesterol level, which is driven by remnant cholesterol in triglyceride-rich lipoproteins. The metabolism and clearance of triglyceride-rich lipoproteins are down-regulated through apolipoprotein C3 (APOC3)-mediated inhibition of lipoprotein lipase.
418. A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection.
作者: Katharina A Mayer.;Eva Schrezenmeier.;Matthias Diebold.;Philip F Halloran.;Martina Schatzl.;Sabine Schranz.;Susanne Haindl.;Silke Kasbohm.;Alexander Kainz.;Farsad Eskandary.;Konstantin Doberer.;Uptal D Patel.;Jaideep S Dudani.;Heinz Regele.;Nicolas Kozakowski.;Johannes Kläger.;Rainer Boxhammer.;Kerstin Amann.;Elisabeth Puchhammer-Stöckl.;Hannes Vietzen.;Julia Beck.;Ekkehard Schütz.;Aylin Akifova.;Christa Firbas.;Houston N Gilbert.;Bilgin Osmanodja.;Fabian Halleck.;Bernd Jilma.;Klemens Budde.;Georg A Böhmig.
来源: N Engl J Med. 2024年391卷2期122-132页
Antibody-mediated rejection is a leading cause of kidney-transplant failure. The targeting of CD38 to inhibit graft injury caused by alloantibodies and natural killer (NK) cells may be a therapeutic option.
419. Autoantibodies Targeting Nephrin in Podocytopathies.
作者: Felicitas E Hengel.;Silke Dehde.;Moritz Lassé.;Gunther Zahner.;Larissa Seifert.;Annabel Schnarre.;Oliver Kretz.;Fatih Demir.;Hans O Pinnschmidt.;Florian Grahammer.;Renke Lucas.;Lea Maxima Mehner.;Tom Zimmermann.;Anja M Billing.;Jun Oh.;Adele Mitrotti.;Paola Pontrelli.;Hanna Debiec.;Claire Dossier.;Manuela Colucci.;Francesco Emma.;William E Smoyer.;Astrid Weins.;Franz Schaefer.;Nada Alachkar.;Anke Diemert.;Julien Hogan.;Elion Hoxha.;Thorsten Wiech.;Markus M Rinschen.;Pierre Ronco.;Marina Vivarelli.;Loreto Gesualdo.;Nicola M Tomas.;Tobias B Huber.; .
来源: N Engl J Med. 2024年391卷5期422-433页
Minimal change disease and primary focal segmental glomerulosclerosis in adults, along with idiopathic nephrotic syndrome in children, are immune-mediated podocytopathies that lead to nephrotic syndrome. Autoantibodies targeting nephrin have been found in patients with minimal change disease, but their clinical and pathophysiological roles are unclear.
420. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
作者: Vlado Perkovic.;Katherine R Tuttle.;Peter Rossing.;Kenneth W Mahaffey.;Johannes F E Mann.;George Bakris.;Florian M M Baeres.;Thomas Idorn.;Heidrun Bosch-Traberg.;Nanna Leonora Lausvig.;Richard Pratley.; .
来源: N Engl J Med. 2024年391卷2期109-121页
Patients with type 2 diabetes and chronic kidney disease are at high risk for kidney failure, cardiovascular events, and death. Whether treatment with semaglutide would mitigate these risks is unknown.
|